Clearmind Medicine shares rise 26.21% premarket after entering development agreement with Polyrizon for intranasal MEAI formulation to enhance bioavailability and clinical advancement.

Clearmind Medicine Inc. (CMND) surged 26.21% in premarket trading following the announcement of a development agreement with Polyrizon Ltd. (PLRZ) to advance an intranasal formulation of its lead non-hallucinogenic neuroplastogen, MEAI. The collaboration leverages Polyrizon’s hydrogel technology to enhance MEAI’s bioavailability, therapeutic efficacy, and patient usability, with intranasal delivery offering advantages such as bypassing first-pass metabolism and faster absorption. The partnership aims to optimize MEAI’s clinical development for addiction-related and CNS disorders, aligning with Clearmind’s strategy to accelerate innovation in underserved mental health markets. The move underscores strategic value creation through advanced drug delivery solutions, likely driving the sharp premarket rally.